Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Ronald P. Gaykema, … , Kevin W. Williams, Michael M. Scott
Ronald P. Gaykema, … , Kevin W. Williams, Michael M. Scott
Published February 20, 2017
Citation Information: J Clin Invest. 2017;127(3):1031-1045. https://doi.org/10.1172/JCI81335.
View: Text | PDF
Research Article Metabolism Neuroscience

Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight

  • Text
  • PDF
Abstract

Peptides derived from pre-proglucagon (GCG peptides) act in both the periphery and the CNS to change food intake, glucose homeostasis, and metabolic rate while playing a role in anxiety behaviors and physiological responses to stress. Although the actions of GCG peptides produced in the gut and pancreas are well described, the role of glutamatergic GGC peptide–secreting hindbrain neurons in regulating metabolic homeostasis has not been investigated. Here, we have shown that chemogenetic stimulation of GCG-producing neurons reduces metabolic rate and food intake in fed and fasted states and suppresses glucose production without an effect on glucose uptake. Stimulation of GCG neurons had no effect on corticosterone secretion, body weight, or conditioned taste aversion. In the diet-induced obese state, the effects of GCG neuronal stimulation on gluconeogenesis were lost, while the food intake–lowering effects remained, resulting in reductions in body weight and adiposity. Our work suggests that GCG peptide–expressing neurons can alter feeding, metabolic rate, and glucose production independent of their effects on hypothalamic pituitary-adrenal (HPA) axis activation, aversive conditioning, or insulin secretion. We conclude that GCG neurons likely stimulate separate populations of downstream cells to produce a change in food intake and glucose homeostasis and that these effects depend on the metabolic state of the animal.

Authors

Ronald P. Gaykema, Brandon A. Newmyer, Matteo Ottolini, Vidisha Raje, Daniel M. Warthen, Philip S. Lambeth, Maria Niccum, Ting Yao, Yiru Huang, Ira G. Schulman, Thurl E. Harris, Manoj K. Patel, Kevin W. Williams, Michael M. Scott

×

Figure 7

Anorexigenic effect of GCG neuronal stimulation is enhanced in DIO Gcg-Cre mice.

Options: View larger image (or click on image) Download as PowerPoint
Anorexigenic effect of GCG neuronal stimulation is enhanced in DIO Gcg-C...
n = 6–7 control and GCG-Gq DREADD mice were fed HCD (Teklad TD88137) ad libitum for 5 months prior to testing. (A) CNO stimulation reduced food intake following an 18-hour fast compared with control CNO-injected littermates (2-way repeated measures ANOVA, significant effects of time [F3,33 = 72.91, ****P < 0.0001] and CNO treatment [F1,11 = 36.04, ****P < 0.0001]). (B) Prior to testing the effects of CNO injection on body weight, control and GCG-Gq DREADD mice exhibited no difference in mass (2-way repeated measures ANOVA, F1,11 = 0.02455, P = 0.8783). (C) Regular injections of CNO spaced 12 hours apart significantly reduced body weight in the GCG-Gq DREADD animals but had no effect on controls (2-way repeated measures ANOVA, significant effects of time [F4,44 = 5.02, **P = 0.002] and CNO [F1,11 = 14.59, **P = 0.0028]). (D) Fat mass was reduced (t test, t = 3.76, **P = 0.0032), while no change in lean mass (t test, P = 0.11) was seen. (E and F) No effect of CNO injection on glucose homeostasis was observed. (E) Two-way repeated measures ANOVA, significant effect of time (F4,44 = 42.82, P < 0.0001), no effect of CNO treatment (F1,11 = 4.182, P = 0.655). (F) Two-way repeated measures ANOVA, significant effect of time (F4,44 = 86.73, P < 0.0001), no effect of CNO treatment (F1,11 =4.447, P = 0.0587). No effect of CNO was observed on fed insulin levels (G, t test t = 0.758, P = 0.464) or on glucose uptake (H, n = 3 mice per group, t test for each tissue sourced from CNO-treated WT and GCG-Gq DREADD animals, EDL t = 0.058, P = 0.958; TA t = 1.604, P = 0.1840; soleus t = 0.2589, P = 0.8085; WAT t = 0.8964, P = 0.4207; liver t = 1.200, P = 0.2964).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts